Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from a 35-week interim analysis of the Phase 3...

Related Keywords

Portugal ,Porto ,United States ,America ,Centro Hospitalar Universit ,Eugene Schneider ,Teresa Coelho ,Astrazeneca ,Prnewswire Ionis Pharmaceuticals Inc ,Twitter ,Drug Administration ,Ionis Pharmaceuticals Inc ,Ionis Pharmaceuticals ,Nasdaq ,New Drug Application ,Neuropathy Impairment Score ,Norfolk Quality ,Life Questionnaire Diabetic Neuropathy ,Conjugated Antisense ,Hospital Santo Ant ,Latin America ,Orphan Drug Designation ,Hereditary Transthyretin Amyloidosis ,Nc ,